Hemoglobin-based oxygen carriers: current status and future directions.
Silverman
Toby A
TA
Office of Blood Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20852, USA. toby.silverman@fda.hhs.gov
Weiskopf
Richard B
RB
D000208:Acute Disease; D000818:Animals; D001794:Blood Pressure; D001802:Blood Substitutes; D002986:Clinical Trials as Topic; D005919:Glomerular Filtration Rate; D006454:Hemoglobins / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology; D009203:Myocardial Infarction / Q000209:etiology; D009569:Nitric Oxide / Q000502:physiology; D009572:Nitrite Reductases / Q000378:metabolism; D010100:Oxygen / Q000097:blood*; D010195:Pancreatitis / Q000209:etiology; D012107:Research Design; D012771:Shock, Hemorrhagic / Q000628:therapy
D001802:Blood Substitutes; D006454:Hemoglobins; D009569:Nitric Oxide; D009572:Nitrite Reductases; D010100:Oxygen